Home Applications 213388 Application 213388
Type NDA
Sponsor ABBVIE INC Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 ORIAHNN ELAGOLIX;ESTRADIOL NORETHINDRONE ACETATE;ELAGOLIX CAPSULE;ORAL 300MG;1MG,0.5MG;300MG Yes No
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N213388-001 ORIAHNN (COPACKAGED) ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE CAPSULE / ORAL RLD, RS 2020-05-29
Orange Book patents# Current patent rows page 1 of 1 · 7 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N213388-001 11459305 2028-11-07 U-2842 Drug product 2022-11-02 N213388-001 7419983 2029-07-06 Drug substance, Drug product 2020-06-29 N213388-001 10881659 2034-03-14 U-2842 2021-02-03 N213388-001 11045470 2034-03-14 U-2842 2021-07-27 N213388-001 12083227 2038-08-20 U-2842 Drug product 2024-10-08 N213388-001 11542239 2039-07-23 Drug substance, Drug product 2023-02-06 N213388-001 11690845 2040-08-27 U-3655 2023-08-02
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 41 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N213388-001 ORIAHNN (COPACKAGED) EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE CAPSULE / ORAL RLD, RS 2020-05-29 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 7 · 256 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N213388-001 11459305 2028-11-07 U-2842 Drug product 2022-11-02 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213388-001 7419983 2029-07-06 Drug substance, Drug product 2020-06-29 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213388-001 10881659 2034-03-14 U-2842 2021-02-03 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213388-001 11045470 2034-03-14 U-2842 2021-07-27 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213388-001 12083227 2038-08-20 U-2842 Drug product 2024-10-08 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213388-001 11542239 2039-07-23 Drug substance, Drug product 2023-02-06 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213388-001 11690845 2040-08-27 U-3655 2023-08-02 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N213388-001 11459305 2028-11-07 U-2842 Drug product 2022-11-02 c2088c7a36db…2026-10-15 13:18:30 2026-09 N213388-001 7419983 2029-07-06 Drug substance, Drug product 2020-06-29 c2088c7a36db…2026-10-15 13:18:30 2026-09 N213388-001 10881659 2034-03-14 U-2842 2021-02-03 c2088c7a36db…2026-10-15 13:18:30 2026-09 N213388-001 11045470 2034-03-14 U-2842 2021-07-27 c2088c7a36db…2026-10-15 13:18:30 2026-09 N213388-001 12083227 2038-08-20 U-2842 Drug product 2024-10-08 c2088c7a36db…2026-10-15 13:18:30 2026-09 N213388-001 11542239 2039-07-23 Drug substance, Drug product 2023-02-06 c2088c7a36db…2026-10-15 13:18:30 2026-09 N213388-001 11690845 2040-08-27 U-3655 2023-08-02 c2088c7a36db…2026-09-14 22:38:34 2026-08 N213388-001 11459305 2028-11-07 U-2842 Drug product 2022-11-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213388-001 7419983 2029-07-06 Drug substance, Drug product 2020-06-29 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213388-001 10881659 2034-03-14 U-2842 2021-02-03 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213388-001 11045470 2034-03-14 U-2842 2021-07-27 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213388-001 12083227 2038-08-20 U-2842 Drug product 2024-10-08 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213388-001 11542239 2039-07-23 Drug substance, Drug product 2023-02-06 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213388-001 11690845 2040-08-27 U-3655 2023-08-02 84e616aacf4f…2026-08-18 06:07:40 2026-07 N213388-001 11459305 2028-11-07 U-2842 Drug product 2022-11-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213388-001 7419983 2029-07-06 Drug substance, Drug product 2020-06-29 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213388-001 10881659 2034-03-14 U-2842 2021-02-03 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213388-001 11045470 2034-03-14 U-2842 2021-07-27 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213388-001 12083227 2038-08-20 U-2842 Drug product 2024-10-08 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213388-001 11542239 2039-07-23 Drug substance, Drug product 2023-02-06 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213388-001 11690845 2040-08-27 U-3655 2023-08-02 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N213388-001 11459305 2028-11-07 U-2842 Drug product 2022-11-02 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213388-001 7419983 2029-07-06 Drug substance, Drug product 2020-06-29 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213388-001 10881659 2034-03-14 U-2842 2021-02-03 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213388-001 11045470 2034-03-14 U-2842 2021-07-27 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213388-001 12083227 2038-08-20 U-2842 Drug product 2024-10-08 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213388-001 11542239 2039-07-23 Drug substance, Drug product 2023-02-06 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213388-001 11690845 2040-08-27 U-3655 2023-08-02 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213388-001 11459305 2028-11-07 U-2842 Drug product 2022-11-02 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213388-001 7419983 2029-07-06 Drug substance, Drug product 2020-06-29 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213388-001 10881659 2034-03-14 U-2842 2021-02-03 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213388-001 11045470 2034-03-14 U-2842 2021-07-27 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213388-001 12083227 2038-08-20 U-2842 Drug product 2024-10-08 31067a03dcf5…
Observed Orange Book exclusivity history# openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join Oriahnn ELAGOLIX AND ESTRADIOL AND NORETHISTERONE AbbVie Inc. 99f6eee7-7e52-6999-7eb8-488d06dd1710 2025-12-19 Boxed warning, Warnings, Adverse reactions Exact identifier application applno (NDA): 213388 application number: NDA213388 ndc (product): 0074-1017
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 5 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 0074-1017 Oriahnn Elagolix and Estradiol and Norethisterone AbbVie Inc. NDA Current 0074-1017 Oriahnn Elagolix and Estradiol and Norethisterone AbbVie Inc. NDA Current 0074-1017 Oriahnn Elagolix and Estradiol and Norethisterone AbbVie Inc. NDA Current 0074-1017 Oriahnn Elagolix and Estradiol and Norethisterone AbbVie Inc. NDA Current 0074-1017 Oriahnn Elagolix and Estradiol and Norethisterone AbbVie Inc. NDA Current